drugset / Trial / NCT06938282

An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

NCT06938282

Phase 2 Not yet recruiting 60 enrolled Shanghai Zhongshan Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of HRS-4642 in combination with immunotherapy and chemotherapy in borderline resectable, locally advanced/metastatic pancreatic cancer

Timeline

Start
2025-05-01
Primary completion
2027-04-30
Completion
2029-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-4642 Unknown